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Introduction: To understand the pathways involved in drug clearance from the body, 2 
quantitative evaluations of the hepatobiliary transport of drugs are important. The organic 3 
anion transporting polypeptide (OATP) family transporter, particularly OATP1B1 and 1B3, 4 
are considered to play an important role in hepatic uptake of organic anion compounds. 5 
Pitavastatin is a substrate of OATP, and it includes a fluorine group. Therefore, it represents 6 
an acceptable positron-emission tomography (PET) probe using F-18 to image in vivo hepatic 7 
transporter functions.  8 
Method: [18F]Pitavastatin was synthesized using the method we previously reported. To 9 
evaluate the potential of [18F]pitavastatin in PET imaging of in vivo OATP functions, we 10 
investigated the hepatic uptake with/without rifampicin as an OATP inhibitor after 11 
administration in normal SD rats. [18F]Pitavastatin metabolite was evaluated using 12 
reverse-phase thin-layer chromatography (TLC) autoradiography. We subsequently analyzed 13 
the PET image results and demonstrated that [18F]pitavastatin selectively accumulated in the 14 
liver post-administration.  15 
Result and discussion: In metabolite analysis using reverse-phase TLC, we found that the 16 
radioactivity detected in the plasma, liver (>90% intact), and bile mostly originated from the 17 
parent pitavastatin of the PET study (~40 min). [18F]pitavastatin’s hepatic uptake decreased 18 
(approximately 76%) with rifampicin co-administration in PET analysis. Because 19 
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[18F]pitavastatin has lower clearance in rats than other previously reported OATP1B PET 1 
probes, it holds the potential of an imaging probe that has a higher sensitivity in monitoring 2 
hepatic OATP1B function’s changes.  3 
Conclusion: Compared with the previously reported OATP imaging probes, [18F]pitavastatin 4 
is more suitable for the sensitive detection of functional changes in OATP transporters. We 5 
believe that [18F]pitavastatin enables quantitative analysis of the hepatobiliary transport 6 
system for organic anion compounds. 7 
 8 
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The assessment of hepatobiliary drug transport represents an important factor in 2 
understanding the pathways involved in drug clearance from the body. In humans, numerous 3 
uptake and efflux transporters are coordinately involved in the hepatobiliary transport of 4 
drugs [1,2]. The organic anion transporting polypeptide (OATP) family transports substrates 5 
in a Na+ ion-independent manner [3]. In particular, the OATPs 1B1 and 1B3 play an 6 
important role in the hepatic uptake of organic anion compounds. These transporters are 7 
selectively expressed in the human liver. Of note, they recognize substrates that have anions 8 
of extremely diverse structures. Among the substrates, several drugs used in the clinic can be 9 
identified (e.g., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors 10 
(statins), angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists 11 
(sartans), and various anticancer drugs) [4]. Altered functions of these transporters, caused by 12 
drug–drug interactions and genetic polymorphisms of specific transporter isoforms, result in 13 
changes not only of blood–drug concentrations but also of intrahepatic drug concentrations. 14 
Based on the extended clearance concept, At present, human liver samples (i.e., frozen 15 
hepatocytes and liver tissue blocks) are available, and prediction of liver uptake in humans is 16 




Nuclear medicine imaging technology is attracting attention as a functional diagnostic 1 
method that enables noninvasive and specific molecular imaging with high sensitivity in 2 
living systems. Among others, positron-emission tomography (PET) is superior to 3 
single-photon emission computed tomography in terms of sensitivity and quantitative 4 
analysis. In recent years, several PET probes (e.g., [11C]15R-TIC [5, 6], 5 
[11C]dehydropravastatin [7, 8], [11C]telmisartan [9], [11C]rosuvastatin [10], and [18F]LCATD 6 
[11]) have been developed to directly characterize in vivo the hepatobiliary transport systems 7 
for organic anions (Figure 1) [6]. An important feature of PET probes for the quantification 8 
of transport functions is that the probes themselves must not undergo extensive metabolism. 9 
Otherwise, the pharmacokinetic parameters determined represent a complex of intrinsic 10 
parameters for metabolism and membrane transport.  11 
In addition, almost developed PET probes used to examine hepatobiliary transport were 12 
previously labeled with 11C. While handling these compounds, time constraints were 13 
considered. The higher achievable activity for production and the longer half-lives of 14 
18F-labeled probes are clear advantages over 11C-probes for both pre-clinical and clinical PET 15 
imaging. As a consequence, there still exists a need to develop 18F-labeled compounds with 16 
longer half-lives. However, till date, 18F-tracer has only been developed as 18F-labeled bile 17 
acid derivative [18F]LCATD. In the present study, pitavastatin, an antihyperlipidemic agent, 18 
was selected as the maternal compound for the PET imaging probe. Pitavastatin clears 19 
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predominantly from the liver, where OATP1B1 and OATP1B3 play pivotal roles in its uptake 1 
[12]. As a consequence, pitavastatin is expected to have a unique pharmacokinetic character. 2 
Pitavastatin has a fluorine group in its structure. Therefore, by using 18F, a PET nuclide, a 3 
PET imaging probe can be made while maintaining the physical and chemical properties. In 4 
an earlier study, we developed a synthetic method of [18F]pitavastatin using the Suzuki 5 
coupling reaction with 4-[18F]fluoroiodobenzene ([18F]FIB) [13] (Figure 1). In the present 6 
study, we aimed at characterizing the hepatobiliary transport of [18F]pitavastatin in rats by 7 
PET imaging with co-administration of rifampicin, a typical OATP1B inhibitor. 8 
 9 
  10 
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Materials and Methods 1 
Materials 2 
All reagents and solvents used in the present study were commercially available. Specifically, 3 
we purchased them from Wako Pure Chemical Industries (Tokyo, Japan), Nacalai Tesque 4 
(Kyoto, Japan), Merck (Darmstadt, Germany), and Sigma Aldrich (St. Louis, MO, USA). 5 
Reagents and solvents were used as received, without further purification. The identity and 6 
concentration of [18F]pitavastatin were assessed by high-performance liquid chromatography. 7 
To this end, we used a Shimadzu system (a LC-20AT pump with an SPD-20A UV detector, 8 
σ=220, 254nm; Shimadzu, Kyoto, Japan) with a Cosmosil 5C18-AR-II column (4.6 × 150 9 
mm and 10 × 250 mm; Nacalai Tesque) and a radioisotope detector. 10 
 11 
Synthesis of [18F]pitavastatin 12 
[18F]Pitavastatin was synthesized as previously reported [13].  13 
Radiochemistry 14 
[18F]Fluoride was produced using a cyclotron (CYPRIS HM-18, Sumitomo Heavy Industries, 15 
Tokyo, Japan) via an 18O (p,n) 18F reaction and passed through a Sep-Pak Light QMA 16 
cartridge (Waters Corporation, Milford, MA, USA) as an aqueous solution in 18O-enriched 17 
water. The cartridge was then dried using N2, and 18F activity was eluted using 1.0 mL of a 18 
Kryptofix2.2.2 (Merck)/K2CO3 solution [9.5 mg of Kryptofix2.2.2 and 1.7 mg of K2CO3 in 19 
MeCN/water (96/4)]. The solvent was removed by azeotropic dehydration with MeCN (1.0 20 
mL) at 120°C under a stream of argon gas for 10 min. 21 
Synthesis of 4-[18F]Fluoroiodobenzene 22 
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A solution of 4-iodophenyldiphenylsulfonium triflate (2.00 mg) in MeCN (150 μL) was 1 
added to a reaction vessel containing the 18F activity (1.10–1.50 GBq), and the reaction 2 
mixture was heated for 1 min under microwave irradiation (50.0 W). The resulting mixture 3 
was cooled for 1 min and then passed through a Sep-Pak Light C18 column (Waters) and 4 
washed with water (10 mL). A stream of N2 gas was passed over the column for 10 s, and 5 
4-[18F]fluoroiodobenzene was eluted using MeCN (500 μL). The eluent containing 6 
4-[18F]fluoroiodobenzene was purified using HPLC [radiochemical yield 56.2% ± 3.1% 7 
decay corrected, data are the mean ± SD (n = 3)]. 8 
Synthesis of [18F]pitavastatin using the Suzuki-coupling 9 
A solution of [18F]fluoroiodobenzene in MeCN (185–222 MBq, 100–150 μL) was added to a 10 
solution of boronic ester precursor (2.0 mg), tris(dibenzylideneacetone)dipalladium(0) (1.0 11 
mg) and cesiumcarbonate (4.0 mg) in MeCN (100 µL); the resulting mixture was heated to 12 
100°C under microwave irradiation (50.0 W) for 1 min. The mixture was then passed through 13 
the COSMONICE(R) Filter (S) (0.45 µm, 4 mm) and purified using preparative HPLC 14 
[Cosmosil 5C18-ARII 10 × 250 mm column, MeOH/20 mM phosphate buffer (pH 2.5) = 15 
70/30, flow rate 5.0 mL/min] to obtain a pure solution of [18F]pitavastatin [Rt = 8.5 min, 16 
radiochemical yield: 12.1% ± 3.0% decay corrected from [18F]fluoride ions (mean ± SD, n = 17 





Male Sprague Dawley (SD) rats weighing 222–333 g (8–10 weeks old) were purchased from 2 
Japan SLC, Inc. (Shizuoka, Japan). All animals were kept in a temperature- and 3 
light-controlled environment with standard food. Tap water was provided ad libitum. All 4 
animal procedures were approved by the Kyoto University Animal Care Committee. 5 
 6 
PET Scans 7 
All PET and computed tomography (CT) scans were performed using a FX-3300 (Gamma 8 
Medica, Salem, NH, USA), specifically designed for laboratory animals. Specifically, this 9 
PET scanner has a spatial resolution of <1 mm in full width at half-maximal at the center of 10 
the view at 100 mm in diameter and an axial extent of 110 mm in length. Control SD rats 11 
were used for PET experiments with [18F]pitavastatin alone. Rats were anesthetized and 12 
maintained under anesthesia with 1.5% isoflurane. Additionally, the femoral artery was 13 
cannulated with polyethylene tubing for blood collection. At the start of the emission scan, 14 
[18F]pitavastatin was administered as a single bolus (<85.1 nmol) via the tail vein [dosage: 15 
7.06 ± 1.49 MBq; data are presented as mean ± SD (n = 3)]. All PET acquisitions were 16 
performed in dynamic scan mode for 60 min. Conversely, we intravenously infused 17 
rifampicin, a typical inhibitor of OATP1Bs, to estimate the transport function of OATP1Bs in 18 
the liver as an OATP inhibition model [7]. Rifampicin infusion occurred at a rate of 1.5 19 
11 
 
µmol/min/kg for at least 90 min prior to the administration of [18F]pitavastatin. Additionally, 1 
a constant infusion rate was maintained until the PET scan was concluded (in total, 50–75 2 
µmol of rifampicin was used for blocking scan). Blood sampling time points were as follows: 3 
10, 20, 30, 40, and 50 s and 1, 2, 5, 10, 20, and 30 min after bolus administration of 4 
[18F]pitavastatin. Additionally, the total blood volume sampled from each rat was maximum 5 
160 µL, which did not exceed 1% of the total circulating blood volume (1.6 mL) as 6 
approximately 10 µL of blood was sampled at each time point. Of note, such blood sampling 7 
causes very less damage in rats. Blood radioactivity levels were measured using a µFmPC 8 
system (Shimadzu). Radioactivity in each measured sample was corrected for decay. 9 
Following the PET scan, CT scans were performed. To this end, the following conditions 10 
were used: tube voltage, 60 kV; tube current, 310 µA. Anesthesia was maintained at 1.5% 11 
isoflurane pre-euthanasia, using an injection of sodium pentobarbital. 12 
 13 
Analysis of PET Imaging 14 
PET images were reconstructed by Fourier rebinning and standard 3D ordered-subset 15 
expectation maximization. Regions of interest (ROIs) representing the liver were delineated 16 
using the Pmod program (v. 3.3; PMOD Technologies, Zurich, Switzerland). All the ROIs 17 
were combined and transformed to volumetric ones. The time-radioactivity curve for the liver 18 
12 
 
was performed by normalizing decay-corrected time-radioactivity measurements to 1 
[18F]pitavastatin’s injected dose (% dose). 2 
 3 
Biodistribution of Radioactivity After [18F]pitavastatin Administration 4 
Rats were injected in the tail vein with a saline solution of [18F]pitavastatin. Animals were 5 
sacrificed at specific time points [i.e., 2, 5, 10, 15, 30, and 60 min postinjection; data are 6 
presented as mean ± SD (n = 5)]. We quickly removed samples of the blood, heart, lung, liver, 7 
spleen, pancreas, stomach, intestine, kidney, bone, and whole brain. The tissues’ radioactivity 8 
was measured with a 1480 WIZARD 3 automatic gamma counter (PerkinElmer Co., Ltd.). 9 
Finally, results were expressed as the percentage of the injected dose (%ID). All radioactivity 10 
measurements were corrected for decay. 11 
 12 
Analysis of Metabolites in the Blood, Bile, and Liver Using Thin-Layer Chromatography 13 
(TLC) 14 
Metabolite analysis was executed as previously described [6]. We first performed cannulation 15 
of the femoral artery and the bile duct in the SD rat. Then, [18F]pitavastatin was injected via 16 
the tail vein at a dosage of 40MBq. Arterial blood samples were collected at 1, 2, 5, 10, 20, 17 
and 40 min postinjection. Additionally, bile samples were collected at 0–5, 5–10, 10–25, and 18 
25–40 min postinjection. In order to perform liver tissue sampling, blood flow was 19 
13 
 
terminated by transection of the abdominal aorta and vein at 10 and 40 min postinjection. The 1 
liver was then quickly removed and homogenized. Additionally, precipitation with 2 
acetonitrile was used to deproteinize blood, bile, and liver samples. After centrifugation 3 
(12000 rpm, 2 min, 0°C), the supernatants were applied to RP-18 TLC plates (Merck KGaA, 4 
Darmstadt, Germany). 5 
Plates were developed at room temperature using acetonitrile/water/acetic acid (50:50:0.75) 6 
as a mobile phase. After migration, plates were dried and exposed to BAS SR2040 imaging 7 
plates (Fuji Film, Tokyo, Japan) for 90–360 min. Radioactivity’s distribution on the imaging 8 
plates was determined by digital PSL autoradiography using a Fuji BAS-5000 analyzer. 9 
Subsequently, data was analyzed using the MultiGauge image analysis program (Fuji Film). 10 
Rf value was determined pitavastatin and a lactone form of pitavastatin which was 11 
synthesized [13]. 12 
 13 
Kinetic Analyses of PET Data to Determine the Clearance of Radioactivity 14 
Radioactivity’s initial uptake clearance in the liver (CLuptake,liver) was calculated by 15 
integration plot analyzes [14]. To this end, the initial linear portion of the curves after 16 
[18F]pitavastatin administration (0.5–5 min) was used. The CLuptake,liver of [18F]pitavastatin 17 
was estimated based on the following equation: 18 
 𝑋𝑋𝑡𝑡,𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
𝐶𝐶𝑡𝑡,𝑏𝑏𝑙𝑙𝑏𝑏𝑏𝑏𝑏𝑏 = 𝐶𝐶𝐶𝐶𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢,𝑙𝑙𝑙𝑙𝑙𝑙𝑢𝑢𝑙𝑙 × 𝐴𝐴𝐴𝐴𝐶𝐶0−𝑡𝑡,𝑏𝑏𝑙𝑙𝑏𝑏𝑏𝑏𝑏𝑏𝐶𝐶𝑡𝑡,𝑏𝑏𝑙𝑙𝑏𝑏𝑏𝑏𝑏𝑏 + 𝑉𝑉𝐸𝐸,𝑙𝑙𝑙𝑙𝑙𝑙𝑢𝑢𝑙𝑙 , (1) 19 
14 
 
where Xt,liver, Ct,blood, and AUC0-t,blood represent the amount of radioactivity in the liver at time 1 
t, the blood concentration of radioactivity at time t, and the area under the blood 2 
concentration–time curve from time 0 to t, respectively. VE,liver represents the initial 3 
distribution volume in the liver at time 0. This was calculated from the y intercept of the 4 
integration plot. To estimate AUC0-t,blood, radioactivity’s blood concentration–time curve was 5 
fitted to the following two-exponential equation: 6 
CB,t = Ae−αt + Be−βt 7 
to optimize parameters (α, β, A, B). Then, AUC0-t,blood was calculated by means of the 8 
following equation: 9 
 𝐴𝐴𝐴𝐴𝐶𝐶0−𝑢𝑢,𝑏𝑏𝑙𝑙𝑏𝑏𝑏𝑏𝑏𝑏 = 𝐴𝐴𝛼𝛼 ∙ (1− 𝑒𝑒−𝛼𝛼𝑢𝑢) + 𝐵𝐵𝛽𝛽 ∙ �1 − 𝑒𝑒−𝛽𝛽𝑢𝑢� (2) 10 
CLuptake,liver was obtained from the initial slope of the plot of Xt,liver/Ct,blood versus 11 
AUC0-t,blood/Ct,blood. 12 
 13 
Statistical Analysis 14 
Student’s two-tailed t-test was used to identify significant differences in the kinetic 15 
parameters between control and rifampicin-treated rats. We considered as statistically 16 
significant p-values <0.05. 17 
 18 
  19 
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Results and Discussion 1 
Radiometabolite Analysis of [18F]pitavastatin in the Blood, Liver, and Bile by TLC 2 
Autoradiography 3 
Figure 2 shows TLC radiograms in which the extract from plasma, liver, and bile after 4 
[18F]pitavastatin administration was developed by reverse-phase TLC, respectively. In the 5 
present study, we showed that virtually no metabolites were detectable in the blood. When 6 
evaluating the liver extracts, we found that one metabolite (M1) was barely detectable 7 
following the administration of [18F]pitavastatin. However, almost all radioactivity was 8 
derived from intact [18F]pitavastatin (94.6% at 40 min, Supplemental table 1). As for bile 9 
extracts, we identified a lactone form of pitavastatin [13] and two metabolites (M1 and M2). 10 
However, 81.9% of the radioactivity was derived from intact [18F]pitavastatin, 40 min after 11 
[18F]pitavastatin administration (Supplemental table 1). 12 
Results of this study showed that [18F]pitavastatin’s metabolite analysis was in line with 13 
previous reports on [14C]pitavastatin [15, 16]. In the case of [14C]pitavastatin, a previous 14 
study showed that 84, 95, and 85% of the total radioactivity was derived from pitavastatin in 15 
the plasma, liver, and bile 60 min post-intravenous administration of [14C]pitavastatin, 16 
respectively [15, 16]. Of note, these results indicated that most of the radioactivity was 17 
derived from [18F]pitavastatin. Therefore, we believe that the kinetic parameters estimated 18 
from the present PET study correctly reflect pitavastatin’s hepatobiliary transport. 19 
16 
 
Biodistribution of Radioactivity and Effect of Rifampicin Co-administration in the 1 
Abdominal Region Post-intravenous Administration of [18F]pitavastatin 2 
Figure 3 shows the PET image of normal SD rat with/without rifampicin as an OATP 3 
inhibitor after [18F]pitavastatin administration. Additionally, it presents the analysis results 4 
from PET images using the Pmod program. In the control rats’ liver, a maximum of 5 
48.1±1.5% of the injected dose was distributed 8 min post-administration of [18F]pitavastatin. 6 
Additionally, we found a decrease of radioactivity until the PET scan’s end (39.3±1.27%ID at 7 
30 min). Results of the biodistribution study in normal SD rats over time showed that 8 
radioactivity was predominantly present in the liver in the early phase (71.5±3.4%ID at 10 9 
min, Table 1). It then gradually decreased by the end of the examination (54.1±5.1%ID at 30 10 
min). Additionally, we observed that radioactivity’s reduction rates in the liver were similar 11 
among PET scan and biodistribution study. Furthermore, data error was small. These results 12 
suggest that the PET analysis of [18F]pitavastatin was appropriately consistent compared with 13 
the biodistribution study. On the contrary, radioactivity was also detected post-administration 14 
of [18F]pitavastatin in the kidney at early time points and in the intestine at a later time point 15 
(30 min). However, similarly to a separate conventional biodistribution study, in the PET 16 
scan, no clear distribution of radioactivity to other tested organs was observed (Table 1). 17 
These results are consistent with a previous study of [14C]pitavastatin. Specifically, an earlier 18 
whole-body autoradiography of rats that received an intravenous administration of 19 
17 
 
[14C]pitavastatin indicated that radioactivity mainly accumulated in the liver and kidney at 1 
2.5 min, while high levels of radioactivity were found in the liver and intestine 60 min 2 
post-administration [15, 16]. We think that OATP1A2 expressed in the kidney affected early 3 
uptakepitavastatin as this drug has less contribution to OATP1A2 compared with that to 4 
OATP1B1 [3, 17, ]. In rifampicin-treated rats, as shown in Figure 3, we found that the 5 
amount of radioactivity accumulated in the liver and intestine was noticeably less than in 6 
control rats (no rifampicin). Furthermore, the liver’s maximum radioactivity (31.6 ± 4.9% at 7 
8 min) decreased to 65% compared with control rats (p < 0.05; Student’s two-tailed t-test). 8 
Such results suggested that the hepatobiliary transport of [18F]pitavastatin was modified by 9 
co-administration with rifampicin, an OATP inhibitor. On the contrary, radioactivity’s blood 10 
concentration became significantly higher even 2 min after [18F]pitavastatin administration vs. 11 
control rats. Furthermore, radioactivity levels in the liver and intestine were found to be 12 
significantly lower. In the present study, the protocol of rifampicin administration used 13 
(constant infusion of 1.5 µmol/min/kg for >90 min) was the same as the one used in previous 14 
PET studies with [11C]dehydropravastatin and [11C]telmisartan [7, 9]. Specifically, unbound 15 
blood concentration of rifampicin was 11–13 µM at steady state in rats. This value is 16 
sufficiently high to potently inhibit rat Oatp1a4 (Ki = 1.46 µM) and Oatp1b2 (Ki = 0.79 µM) 17 




Kinetic Analyses of PET Data to Determine Radioactivity’s Clearance 1 
Radioactivity in blood samples was eliminated in a biphasic manner in both control and 2 
rifampicin-treated rats (Fig. 3C). However, with co-administration of rifampicin, 3 
radioactivity’s elimination was delayed. Additionally, its blood AUC0-30, normalized by 4 
[18F]pitavastatin’s dose, was 3.4-fold larger in rifampicin-treated rats [111.4 ± 34.9 (% of 5 
dose/mL*min)] than in control SD rats [33.1 ± 5.0 (% of dose/mL*min); p < 0.05; Student’s 6 
two-tailed t-test]. Similarly, these results indicate that blood concentration increased due to 7 
liver uptake inhibition by rifampicin. Integration plots for hepatic uptake clearance 8 
(CLuptake,liver) are shown in Figure 4A, and their kinetic parameters are summarized in Figure 9 
4B. Linearity of the plot was maintained for a short time period between 0.5–5 min for liver 10 
uptake. In control rats, CLuptake,liver was 9.08 ± 1.33 mL/min/kg, while in rifampicin-treated 11 
rats, CLuptake,liver significantly decreased to 26% of the control values (2.33 ± 0.11 mL/min/kg, 12 
p < 0.05; Student’s two-tailed t-test). Of note, the degree of decrease in CLuptake,liver of 13 
[18F]pitavastatin was noticeably smaller with respect to previous reported probes as 14 
[11C]telmisartan (65% of control) and [11C]dehydropravastatin (69% of control) [7, 9]. These 15 
differences can partially be explained by the fact that the CLuptake,liver values of 16 
[11C]telmisartan (63 ± 11 mL/min/kg) [7] and [11C]dehydropravastatin (73.6 ± 4.8 17 
mL/min/kg) [9] were almost equal to the hepatic blood flow rate (55 mL/min/kg). This result 18 
implies that it was difficult to accurately calculate the intrinsic hepatic uptake clearance in 19 
19 
 
rats [20, 21]. Conversely, this value of [18F]pitavastatin (9.08 ± 1.33 mL/min/kg) was 1 
one-sixth of the hepatic blood flow rate. Therefore, we believe that [18F]pitavastatin can be 2 
used to estimate the intrinsic hepatic uptake clearance in rats in an in vivo PET study. 3 
Furthermore, pitavastatin’s in vitro uptake clearance in rat hepatocytes was reported to be 4 
121–444 µL/min/mg protein [22, 23]. The latter corresponds to a CLuptake,liver of 10.4–26.1 5 
mL/min/kg, assuming a well-stirred model with physiological scaling factors (1.2 × 6 
108cells/g liver, 41.2 g liver/kg; fB of pitavastatin in rats, 0.021) [23, 24]. Thus, hepatic 7 
clearance determined from the in vitro study of pitavastatin is similar to that determined from 8 
the PET analysis of [18F]pitavastatin. As a result, [18F]pitavastatin has the potential of a 9 
higher sensitivity in detecting the inhibitory effects of drugs on hepatic OATP1B transporters 10 
vs. other reported OATP imaging probes. 11 
 12 




In summary, in the present feasibility study, the kinetic analyzes of [18F]pitavastatin’s 2 
hepatobiliary transport in rats were carried out using PET imaging. As expected, 3 
intravenously infusion of rifampicin, a typical OATP inhibitor, reduced hepatic uptake. Such 4 
findings confirmed that, in the rat’s liver, [18F]pitavastatin’s membrane transport was 5 
predominantly transporter mediated. [18F]pitavastatin can quantitatively detect changes in the 6 
hepatobiliary transport of an OATP inhibition model of rats. Compared with previously 7 
reported OATP imaging probes, especially [11C]dehydropravastatin and [11C]telmisartan, we 8 
can found that [18F]pitavastatin is suitable for the sensitive detection of functional changes in 9 
OATP transporters. We believe that this finding is due to drug–drug interactions and genetic 10 
polymorphisms of specific transporter isoforms by [18F]pitavastatin. Of note, 11 
[18F]pitavastatin’s hepatic clearance was not limited by hepatic blood flow rate. Pitavastatin 12 
has been used as an antihyperlipidemic drug for many years. We believe that the 13 
pharmacokinetic properties identified here are also applicable to humans. Specifically, we 14 
expect that [18F]pitavastatin performs similarly in detecting functional changes in OATP1Bs 15 
in human PET studies.  16 
 17 
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 2 
Table 1. Time-dependent tissue distribution of radioactivity after intravenous administration 3 
of [18F]pitavastatin. 4 
 %ID/organ ± SD (n = 5) 
2 min 5 min 10 min 15 min 30 min 60 min 
Blooda 11.63±1.31 4.57±0.59 2.80±0.21 1.97±0.15 1.26±0.16 1.35±0.75 
Heart 0.19±0.01 0.12±0.01 0.11±0.01 0.11±0.01 0.12±0.02 0.12±0.04 
Lung 0.30±0.02 0.18±0.04 0.11±0.02 0.09±0.02 0.03±0.01 0.06±0.03 
Liver 69.56±1.66 70.11±2.74 71.54±3.40 68.05±6.38 54.11±5.13 32.61±3.69 
Pancreas 0.22±0.08 0.06±0.03 0.06±0.02 0.05±0.04 0.03±0.02 0.04±0.02 
Spleen 0.08±0.01 0.04±0.01 0.02±0.00 0.02±0.01 0.01±0.01 0.02±0.02 
Stomach 0.18±0.03 0.29±0.21 0.10±0.10 0.34±0.31 0.28±0.33 0.12±0.04 
Intestine 4.00±0.30 8.20±0.90 13.33±3.72 20.22±2.79 33.78±5.74 64.86±7.72 
Kidney 7.46±0.37 2.13±0.34 1.25±0.27 0.97±0.25 0.68±0.10 0.55±0.19 
Boneb 0.12±0.02 0.07±0.01 0.04±0.01 0.04±0.02 0.04±0.04 0.02±0.03 
a Assuming that weight of blood in rats was 10% of total body weight. b data is presented 5 




Figure legends 1 
Figure 1. Chemical structure of the PET probe for OATP evaluation. (A) [11C]15R-TIC-Me, 2 
(B) [11C]dehydropravastatin, (C) [11C]telmisartan, (D) [11C]rosuvastatin, (E) [18F]pitavastatin 3 
(present study) 4 
 5 
Figure 2. Representative TLC autoradiograms on the radio metabolite analysis following 6 
intravenous administration of [18F]pitavastatin in normal rat. 7 
Each line represents an authentic [18F]pitavastatin sample [pitavastatin (aus.)] and blood, liver, 8 
and bile extract samples collected at the designated time points following [18F]pitavastatin’s 9 
intravenous administration. We have confirmed that pitavastatin lactone band’s location is 10 
identical to the Rf values of the pitavastatin lactone that we created (Rf=0.13–0.14) 11 
 12 
Figure 3. PET images of rat abdominal regions taken post-intravenous administration of 13 
[18F]pitavastatin (anesthesia: 1.5% isoflurane; dosage: 7.06 ± 1.49 MBq; n = 3). Colonal 14 
maximum intensity projecting PET images of radioactivity in the abdominal region were 15 
captured at 2, 5, 10, 20, and 30 min in control rats (A), rifampicin-treated rats at an infusion 16 
rate of 1.5μmol/min/kg (B). 17 
Radioactivity’s time profiles in blood from the μFmPC system (C) and liver were determined 18 
by PET imaging analysis 30 min post-intravenous administration of [18F]pitavastatin. (D) 19 
Each symbol represents the control and rifampicin-treated rats (1.5 mmol/min/kg for at least a 20 
29 
 
90 min PET scan). The data represent the mean ±SD. (n=3; Students t-test, * p<0.05, †<0.01, 1 
‡<0.005) Inset figures show the data points within 5 min 2 
Figure 4. (A) Integration plots were drawn for the calculation of hepatic uptake of total 3 
radioactivity in control and rifampicin-treated rats. The data represent the mean ± SD (n=3). 4 
(B) [18F]pitavastatin’s pharmacokinetic parameters after its intravenous administration in rats. 5 
The values represent the mean ± SD (n=3; Students t-test, * p<0.05) 6 
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Figure 2 4 
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